Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke
Creators: name: Worthmann, Hans
name: Dengler, Reinhard
name: Schumacher, Helmut
name: Schwartz, Andreas
name: Eisert, Wolfgang G.
name: Lichtinghagen, Ralf
name: Weissenborn, Karin
Publisher: name: Basel : MDPI AG
Year: 2012
Subjects: subject: Acetylsalicylic acid (ASA)
subject: Antithrombotic therapy
subject: Dipyridamole
subject: Ischemic stroke
subject: Monocyte chemoattractant protein-1 (MCP-1)
subject: Neuroprotection
subject: acetylsalicylic acid
subject: dipyridamole
subject: monocyte chemotactic protein 1
subject: antithrombocytic agent
subject: biological marker
subject: CCL2 protein, human
subject: adult
subject: aged
subject: article
subject: brain ischemia
subject: controlled study
subject: disease severity
subject: early intervention
subject: female
subject: human
subject: major clinical study
subject: male
subject: monotherapy
subject: multicenter study
subject: National Institutes of Health Stroke Scale
subject: open study
subject: predictive value
subject: prognosis
subject: protein blood level
subject: randomized controlled trial
subject: transient ischemic attack
subject: blood
subject: drug combination
subject: follow up
subject: middle aged
subject: Stroke
subject: time
subject: very elderly
subject: Adult
subject: Aged
subject: Aged, 80 and over
subject: Aspirin
subject: Biological Markers
subject: Brain Ischemia
subject: Chemokine CCL2
subject: Drug Therapy, Combination
subject: Female
subject: Follow-Up Studies
subject: Humans
subject: Male
subject: Middle Aged
subject: Platelet Aggregation Inhibitors
subject: Time Factors
subject: Dewey Decimal Classification::500 | Naturwissenschaften::540 | Chemie
subject: Dewey Decimal Classification::500 | Naturwissenschaften::570 | Biowissenschaften, Biologie

description: Inflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression. We hypothesized that early treatment with ASA + ER-DP will reduce levels of MCP-1 also in patients with ischemic stroke. The EARLY trial randomized patients with ischemic stroke or TIA to either ASA + ER-DP treatment or ASA monotherapy within 24 h following the event. After 7 days, all patients were treated for up to 90 days with ASA + ER-DP. MCP-1 was determined from blood samples taken from 425 patients on admission and day 8. The change in MCP-1 from admission to day 8 did not differ between patients treated with ASA + ER-DP and ASA monotherapy (p &gt; 0.05). Comparisons within MCP-1 baseline quartiles indicated that patients in the highest quartile (&gt; 217-973 pg/mL) showed improved outcome at 90 days if treated with ASA + ER-DP in comparison to treatment with ASA alone (p = 0.004). Our data does not provide any evidence that treatment with ASA + ER-DP lowers MCP-1 in acute stroke patients. However, MCP-1 may be a useful biomarker for deciding on early stroke therapy, as patients with high MCP-1 at baseline appear to benefit from early treatment with ASA + ER-DP.